512 Aperçu des actions Grand Pharmaceutical Group Limited, une société holding d'investissement, se consacre à la recherche et au développement, à la fabrication et à la vente de préparations pharmaceutiques et de dispositifs médicaux, de produits de biotechnologie et de soins de santé, ainsi que de matières premières pharmaceutiques. Plus de détails
Récompenses Analyse des risques Aucun risque n'a été détecté pour 512 à partir de nos contrôles de risques.
Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
Grand Pharmaceutical Group Limited Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Grand Pharmaceutical Group Historique des cours de bourse Prix actuel de l'action HK$4.74 Plus haut sur 52 semaines HK$5.62 Plus bas sur 52 semaines HK$3.17 Bêta 0.75 Variation sur 1 mois 3.95% Variation sur 3 mois 9.47% Variation sur 1 an 22.80% Variation sur 3 ans -26.96% Variation sur 5 ans 11.79% Évolution depuis l'introduction en bourse -81.77%
Nouvelles et mises à jour récentes
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
Investor sentiment improves as stock rises 15% Oct 02 Voir plus de mises à jour
Grand Pharmaceutical Group Limited Submits New Drug Application for the Global Innovative Product GPN01768 to the National Medical Products Administration of the People's Republic of China Dec 16
Grand Pharmaceutical Group Limited's Global Innovative Intravascular Dual-Mode Imaging System NovasyNC Receives Registration Certificate for Medical Device by National Medical Products Administration of the People's Republic of China Dec 12
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Grand Pharmaceutical Group Limited and Nanjing Kainite Medical Technology Company Limited Announce First Adjustable Intracranial Stent Retriever Product Produce in China Approve for Commercialization by NMPA Oct 22
National Medical Products Administration Accepts Grand Pharmaceutical Group Limited's Phase III Clinical Study Application of ITM-11 Oct 14
Investor sentiment improves as stock rises 15% Oct 02
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Sep 28
Grand Pharmaceutical Group Limited (HKG:512) Looks Inexpensive But Perhaps Not Attractive Enough Sep 19
Grand Pharmaceutical Group Limited Appoints Lam Chit Yee Jessica as Executive Director Aug 27
First half 2024 earnings released: EPS: HK$0.44 (vs HK$0.29 in 1H 2023) Aug 22
Grand Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024 Aug 15
Grand Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 19, 2024 Aug 09
Grand Pharmaceutical Group Limited Announces Executive Changes Jun 24
Executive Chairman recently bought HK$526k worth of stock Jun 21
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment Jun 13
Grand Pharmaceutical Group (HKG:512) Is Paying Out A Larger Dividend Than Last Year Jun 05
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023 Jun 05
Upcoming dividend of HK$0.26 per share May 30
Executive Chairman recently bought HK$271k worth of stock May 25
Market Participants Recognise Grand Pharmaceutical Group Limited's (HKG:512) Earnings May 22
Executive Chairman recently bought HK$489k worth of stock May 11
Grand Pharmaceutical Group Limited, Annual General Meeting, Jun 04, 2024 Apr 28
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26 Apr 25
Executive Chairman recently bought HK$371k worth of stock Apr 21
Executive Chairman recently bought HK$243k worth of stock Apr 06
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26 Mar 25
Dividend increased to HK$0.26 Mar 25
Executive Chairman recently bought HK$381k worth of stock Mar 22
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Full year 2023 earnings: EPS misses analyst expectations Mar 21
Grand Pharmaceutical Group Limited Proposes Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024 Mar 21
Grand Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 19, 2024 Mar 08
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884 Mar 07
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA Dec 27
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application of ARC01 (A002) Nov 03
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial in China of the Groups Global Innovative Ophthalmic Drug GPN00833 Has Completed the First Patient Enrollment and Dosing Oct 25
We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt Oct 20
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching Sep 26
Grand Pharmaceutical Group Limited Announces Phase III Clinical Study in China of the Group's Global Innovation Drug RYaltris® Compound Nasal Spray Has Completed and Successfully Met Primary Endpoint Sep 14
Grand Pharmaceutical Group Limited Announces That the Phase I Clinical Trial of Apad, A Global Innovative Drug Independently Developed by the Group for the Treatment of Sepsis, Has Completed First Subject Enrollment and Dosing Approved Recently Aug 18
First half 2023 earnings released: EPS: HK$0.29 (vs HK$0.20 in 1H 2022) Aug 12
Grand Pharmaceutical Group Limited Announces New Mra Drug of the Group Eplerenone Tablets Was Granted Drug Registration Certificate Aug 04
Grand Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 10, 2023 Aug 01
Grand Pharmaceutical Group Limited Announces Approval by National Medical Products Administration to Conduct Phase II Clinical Study in China Jul 18
Less than half of directors are independent Jul 12
Grand Pharmaceutical Group Limited Appoints Yang Guang as an Executive Director Jul 01
Grand Pharmaceutical Group Limited Announces Resignation of Niu Zhanqi as Executive Director Jun 22
Less than half of directors are independent Jun 08
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14 Jun 04 Grand Pharmaceutical Group Limited Announces Board Changes
Upcoming dividend of HK$0.14 per share at 2.9% yield Jun 02 Grand Pharmaceutical Group Limited Announces the Multicenter Phase III Clinical Trial of Ryaltris Compound Nasal Spray
Is Grand Pharmaceutical Group (HKG:512) A Risky Investment? May 05
Full year 2022 earnings released: EPS: HK$0.59 (vs HK$0.68 in FY 2021) Mar 23 National Medical Products Administration of the People's Republic of China Accepts Grand Pharmaceutical Group Limited's Investigational New Drug Applications of the Group Three Innovative Products in China
Grand Pharmaceutical Group Limited Conducts Clinical Trials of its Innovative Oral Small Molecule 3Cl Protease Inhibitor GS221 Against COVID-19 Dec 29
Investor sentiment improved over the past week Dec 29
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly Nov 21
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 07
Grand Pharmaceutical Group Limited Announces NMPA Approves Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX591-CDx Oct 18
Grand Pharmaceutical Group Limited Announces Clinical Trial Application in China for Global Innovative Radionuclide-Drug Conjugate TLX250-CDX Approved by NMPA Sep 29
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount? Sep 05
Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly Aug 16
First half 2022 earnings released Aug 11
Grand Pharmaceutical Group Limited Provides Unaudited Earnings Guidance for Six Months Ended 30 June 2022 Aug 06
Grand Pharmaceutical Group Announces Clinical Trial Applications in China for Global Innovative Radionuclide-Drug Conjugates TLX591-CDX AND TLX250-CDX Accepted by NMPA Aug 02
Grand Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 10, 2022 Jul 30
Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching Jul 28
Executive Director recently bought HK$535k worth of stock Jun 10
Upcoming dividend of HK$0.11 per share May 30
Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11 May 29
Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2021 May 28
Full year 2021 earnings released: EPS: HK$0.68 (vs HK$0.52 in FY 2020) Apr 28
Less than half of directors are independent Apr 27
Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount? Apr 08
Grand Pharmaceutical Group Limited Announces Phase III Clinical Trial of Global Innovative Drug Ryaltris Compound Nasal Spray Successfully Completed the First Patient Enrollment in China Apr 08
Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet Mar 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 18
Now 21% undervalued after recent price drop Mar 07
Sirtex Medical and Grand Pharmaceutical Group Limited Receive NDA Approval of SIR-Spheres® Y-90 Resin Microspheres in China from the National Medical Products Administration Feb 10
Investor sentiment deteriorated over the past week Jan 27
If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late Jan 24
These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely Dec 13
Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price Nov 27
With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting Oct 25
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Sep 25
China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly Sep 01
First half 2021 earnings released: EPS HK$0.34 (vs HK$0.21 in 1H 2020) Aug 11
China Grand Pharmaceutical and Healthcare Holdings Limited (SEHK:512) agreed to acquire 22.2% interest in CoRISMA MCS Systems, Inc for $12 million. Aug 08
Investor sentiment deteriorated over the past week Jul 27
Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention? Jul 12
Executive Deputy Chairman Bo Hu has left the company Jun 09
Executive Chairman Chengwei Liu has left the company Jun 09
China Grand Pharmaceutical and Healthcare Holdings Limited Announces TLX591-CDx Dosed the First Patient in Japan Jun 03
China Grand Pharmaceutical and Healthcare Holdings Limited Declares Final Dividend for the Year Ended December 31, 2020 At the Annual General Meeting Held on June 1, 2021 Jun 02 Rendement pour les actionnaires 512 HK Pharmaceuticals HK Marché 7D 1.3% -3.3% -2.2% 1Y 22.8% -2.4% 18.3%
Voir le rapport complet des actionnaires
Rendement vs Industrie: 512 a dépassé le secteur Hong Kong Pharmaceuticals qui a rapporté -2.4 % au cours de l'année écoulée.
Rendement vs marché: 512 a dépassé le marché Hong Kong qui a rapporté 18.3 % au cours de l'année écoulée.
Volatilité des prix Is 512's price volatile compared to industry and market? 512 volatility 512 Average Weekly Movement 5.6% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.9% 10% most volatile stocks in HK Market 18.7% 10% least volatile stocks in HK Market 4.1%
Cours de l'action stable: 512 n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de 512 ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise Grand Pharmaceutical Group Limited, société holding d'investissement, se consacre à la recherche et au développement, à la fabrication et à la vente de préparations pharmaceutiques et de dispositifs médicaux, de produits de biotechnologie et de soins de santé, ainsi que de matières premières pharmaceutiques. L'entreprise propose des produits liés aux maladies respiratoires, à l'ophtalmologie, aux urgences cérébro-cardiovasculaires et à la biotechnologie. Elle fabrique et vend des produits pharmaceutiques, de la taurine, des produits agrochimiques, des médicaments chimiques et des acides aminés.
Afficher plus Grand Pharmaceutical Group Limited Résumé des fondamentaux Comment les bénéfices et les revenus de Grand Pharmaceutical Group se comparent-ils à sa capitalisation boursière ? 512 statistiques fondamentales Capitalisation boursière HK$16.60b Bénéfices(TTM) HK$2.41b Recettes(TTM ) HK$10.59b
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) 512 compte de résultat (TTM ) Recettes HK$10.59b Coût des recettes HK$4.34b Marge brute HK$6.25b Autres dépenses HK$3.84b Les revenus HK$2.41b
Derniers bénéfices déclarés
Jun 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) 0.69 Marge brute 59.00% Marge bénéficiaire nette 22.75% Ratio dettes/capitaux propres 28.1%
Quelles ont été les performances à long terme de 512?
Voir les performances historiques et les comparaisons Dividendes
5.5% Rendement actuel des dividendes
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2024/12/20 23:13 Cours de l'action en fin de journée 2024/12/20 00:00 Les revenus 2024/06/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes Grand Pharmaceutical Group Limited est couverte par 7 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Yanyin Zhu China International Capital Corporation Limited Xiao Wei Lin Everbright Securities Co. Ltd. Yiling Chen Guosen Securities Co., Ltd.
Afficher 4 plus d'analystes 
